Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study.
暂无分享,去创建一个
Cheuk-Kwan Sun | H. Yip | P. Sung | Li-Teh Chang | Huang-Chung Chen | Cheng-Hsu Yang | Sheng-ying Chung | Tzu-hsien Tsai | Chang-qing Fan | Yung-Lung Chen | Han‐Tan Chai | Cheng‐Hsu Yang
[1] J. Genest. C-reactive protein: risk factor, biomarker and/or therapeutic target? , 2010, The Canadian journal of cardiology.
[2] Michael J. Pencina,et al. Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.
[3] B. Nagalla,et al. Gender-Related Differences in the Relationship between Plasma Homocysteine, Anthropometric and Conventional Biochemical Coronary Heart Disease Risk Factors in Middle-Aged Indians , 2009, Annals of Nutrition and Metabolism.
[4] C. Stefanadis,et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. , 2008, European heart journal.
[5] A. Hamsten,et al. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. , 2006, Atherosclerosis.
[6] Cheuk-Kwan Sun,et al. Strong correlation between serum levels of inflammatory mediators and their distribution in infarct-related coronary artery. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[7] H. Yip,et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. , 2005, International heart journal.
[8] D. Levy,et al. Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death From 1950 to 1999: The Framingham Heart Study , 2004, Circulation.
[9] O. Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[10] E. Vittinghoff,et al. Risk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study , 2003, Annals of Internal Medicine.
[11] S. Vasikaran,et al. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. , 2002, Clinical science.
[12] O. Hess,et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. , 2002, European heart journal.
[13] R. Virmani,et al. Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies , 2002, Circulation.
[14] K. Bushara,et al. Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels , 2002, Clinical cardiology.
[15] F. Corrales,et al. Hyperhomocysteinemia in Liver Cirrhosis: Mechanisms and Role in Vascular and Hepatic Fibrosis , 2001, Hypertension.
[16] A. Reunanen,et al. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? , 2001, Archives of internal medicine.
[17] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[18] B. Horne,et al. Plasma Homocysteine Predicts Mortality Independently of Traditional Risk Factors and C-Reactive Protein in Patients With Angiographically Defined Coronary Artery Disease , 2000, Circulation.
[19] Medina,et al. Homocysteine: an emergent cardiovascular risk factor? , 2000, European journal of clinical investigation.
[20] I. Rosenberg,et al. Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem , 1999, Annals of Internal Medicine.
[21] S. Yusuf,et al. Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.
[22] R. D'Agostino,et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. , 1999, Archives of internal medicine.
[23] S. Yusuf,et al. Emerging epidemic of cardiovascular disease in developing countries. , 1999, Circulation.
[24] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[25] J. Danesh,et al. Plasma Homocysteine and Coronary Heart Disease: Systematic Review of Published Epidemiological Studies , 1998, Journal of cardiovascular risk.
[26] A. Folsom,et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. , 1998, Circulation.
[27] P. McBride,et al. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. , 1998, Archives of internal medicine.
[28] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[29] J. Witteman,et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.
[30] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[31] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[32] P. Ueland,et al. Total homocysteine in plasma or serum: methods and clinical applications. , 1993, Clinical chemistry.
[33] J. Hermiller,et al. Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. , 1992, Catheterization and cardiovascular diagnosis.
[34] P. Ueland,et al. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. , 1989, The Journal of laboratory and clinical medicine.
[35] G. Moneta,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[36] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.
[37] L. Bouter,et al. Follow-Up of the Hoorn Study Hyperhomocysteinemia Increases Risk of Death , Especially in Type 2 Diabetes : 5-Year , 2000 .
[38] Elga,et al. PLASMA HOMOCYSTEINE LEVELS AND MORTALITY IN PATIENTS WITH CORONARY ARTERY DISEASE , 2000 .